BioVersys’ CHF 24.2 Million Series C Financing Round

MLLStart! advised Clinical Research Ventures. Walder Wyss advises BioVersys.BioVersys AG, a privately-held clinical-stage, multi-asset Swiss pharmaceutical company focusing on research and development of therapies for life-threatening…

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here
  Share:
Federica Tiefenthaler

Author: Federica Tiefenthaler

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here